Title : Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Pub. Date : 2020 Nov 17

PMID : 33212896






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., epsilon-aminocaproic acid and tranexamic acid); however, they have adverse side effects. Tranexamic Acid plasminogen activator, tissue type Homo sapiens